Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response. J of Skin [Internet]. 2018 Dec. 17 [cited 2025 May 18];2:S92. Available from: https://skin.dermsquared.com/skin/article/view/489